Helen Torley sold $3.4M of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 60,000 shares at an average of $56.46, traded Jul 8, 2025, filed Jul 10, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.4M at market
- 0Share of holdings soldSold 8.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-019653, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 8, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Jul 10, 2025 |
| Jul 8, 2025 | SOpen-market sale Common Stock10b5-1 | -3,598 | $54.48 | $196k | 750,121 | Jul 10, 2025 |
| Jul 8, 2025 | SOpen-market sale Common Stock10b5-1 | -16,402 | $55.74 | $914k | 733,719 | Jul 10, 2025 |
| Jul 9, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Jul 10, 2025 |
| Jul 9, 2025 | SOpen-market sale Common Stock10b5-1 | -19,792 | $56.43 | $1.1M | 733,927 | Jul 10, 2025 |
| Jul 9, 2025 | SOpen-market sale Common Stock10b5-1 | -208 | $57.08 | $12k | 733,719 | Jul 10, 2025 |
| Jul 10, 2025 | MOption exercise Common Stock10b5-1 | +20,000 | $8.11 | $162k | 753,719 | Jul 10, 2025 |
| Jul 10, 2025 | SOpen-market sale Common Stock10b5-1 | -4,254 | $56.74 | $241k | 749,465 | Jul 10, 2025 |
| Jul 10, 2025 | SOpen-market sale Common Stock10b5-1 | -15,746 | $57.62 | $907k | 733,719 | Jul 10, 2025 |
| Jul 8, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 296,569 | Jul 10, 2025 |
| Jul 9, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 276,569 | Jul 10, 2025 |
| Jul 10, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -20,000 | $8.11 | $162k | 256,569 | Jul 10, 2025 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 37Weak | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $278k 4,263 shares | -25% | |
| 2Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $59k 829 shares | -2% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $137k 2,000 shares | -4% | |
| 14Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $150k 2,000 shares | -4% | |
| 21Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $174k 2,227 shares | -9% | |
| 37Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $1.5M 20,000 shares | -45% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.